8.10 USD
▼+0.53-1.58%
盘后 8.40 +2.07%
2026-08-03
市值
$14.77M
市盈率
—
EPS
-3.04
股息率
—
52 周区间
5.00 – 31.00
成交量
11.05K
Beta
-0.07
目标价
53.50
52W 低 5.0052W 高 31.00
价格走势
公司简介
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company als...